# US 2006/0079498 A1 · Therapeutic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079498 A1
- Document ID: US20060079498A1
- Status: Published application
- Kind: A1
- Application number: 11/282,057
- Filed: 2005-11-16
- Published: 2006-04-13
- Earliest claimed: 2004-05-12
- Assignees: Pfizer Inc.
- Inventors: Bernard Hulin; David Piotrowski
- Web page: https://patentgrep.com/patent/US20060079498A1

## CPC

- C07D 207/14: Nitrogen atoms not forming part of a nitro radical
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/10: for petit-mal
- A61P 25/12: for grand-mal
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 275/06: with hetero atoms directly attached to the ring sulfur atom
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of formula (I), or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt, wherein R1, R2, R3, HET, n, Q, X, Y, and Z are as described herein; compositions thereof; and uses thereof including treating Type 2 diabetes.

## Claims

### Claim 1

A compound of formula (I)
or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt, wherein:
R1 is —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C1-C6)arylalkyl, —NRaRb, hydroxy, cyano, aryl, or heteroaryl, wherein said —(C1-C6)alkyl, said aryl, or said heteroaryl is optionally substituted independently with one to three —COOH, —C(O)(C1-C6)alkoxy, —C(O)(C1-C6)alkyl, —C(O)NRaRb, cyano, halogen, nitro, trifluoromethyl, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C3-C6)cycloalkyl, or phenyl, wherein:
Ra and Rb are, independently, hydrogen, —(C1-C6)alkyl, aryl, or heteroaryl, or
Ra and Rb, taken together with the nitrogen atom to which they are attached, form a four- to six-membered heterocyclic ring, wherein said ring optionally incorporates an additional one or two nitrogen, oxygen, or sulfur ring heteroatoms;
R2 and R3 are, independently, hydrogen, halogen, —(C1-C6)alkyl, or —(C3-C8)cycloalkyl;
Q is a covalent bond, —C(O)—, or —SO2—;
HET is a heterocycloalkyl ring moiety, optionally substituted with: (A) one to four —(C1-C6)alkyl, optionally substituted with one to six halogen atoms, —(C1-C6)alkoxy, cyano, halogen, hydroxy, or —NRaRb, or (B) —(C1-C6)arylalkyl, optionally substituted with one to six halogen atoms, —(C1-C6)alkoxy, cyano, halogen, hydroxy, or —NRaRb;
n is 0 or 1;
when n is 0, X is —CH2—, and Y is —CH2—, —CHF—, or —CF2—;
or when n is 1, X is —CH2—, —CHF—, or —CF213 ; and Y is —CH2—, —CHF—, or —CF2—, provided that X and Y are not both —CH2—; and
Z is hydrogen or cyano.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R1 is aryl or heteroaryl, optionally substituted independently with one to three cyano, halogen, nitro, trifluoromethyl, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C3-C6)cycloalkyl, or phenyl;
R2 is —H or —(C1-C6)alkyl;
R3 is —H or —(C1-C6)alkyl; and
HET is azetidinyl, piperazinyl, piperidinyl, pyrrolidinyl, 5,6-dihydro-8H-imidazo[1,2-a]pyrazin-7-yl, 5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl, or 7,8-dihydro-5H-pyrido[4,3-a]pyrimidin-6-yl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R1 is benzoisothiazolyl, benzisoxazolyl, isothiazolyl, isoxazolyl, oxazolopyridyl, pyrazinyl, pyridinyl, pyrimidinyl, quinolinyl, quinoxalinyl, thiadiazolyl, triazinyl, or 1,1-dioxo-1H-1,2-benzoisothiazolyl;
R2 and R3 are —H;
Q is a covalent bond; and
HET is piperazinyl.

### Claim 4 (depends on 3)

The compound of claim 3 wherein R1 is pyridinyl or pyrimidinyl.

### Claim 5 (depends on 4)

The compound of claim 4 wherein n is 1, X is —CF2— and Y is —CH2—.

### Claim 6 (depends on 1)

The compound of claim 1 selected from the group consisting of
((2S,4S)-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)pyrrolidin-2-yl)-(3,3-difluoropyrrolidin-1-yl)-methanone,
(3,3-difluoropyrrolidin-1-yl)-((2S,4S)-4-(4-(oxazolo[5,4-b]pyridin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)-methanone,
(3,3-difluoropyrrolidin-1-yl)-((2S,4S)-4-(4-(4-methylpyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)-methanone,
((2S,4S)-4-(2-(trifluoromethy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)pyrrolidin-2-yl)-(3,3-difluoropyrrolidin-1-yl)-methanone,
((S)-3-fluoro-pyrrolidin-1-yl)-{(2S,4S)-4-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyrrolidin-2-yl}-methanone,
((S)-3-fluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(2-trifluoromethyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyrrolidin-2-yl]-methanone,
(3,3-difluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(4-oxazolo[4,5-c]pyridin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone,
[(2S,4S)-4-(2-cyclopropyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyrrolidin-2-yl]-(3-fluoro-azetidin-1-yl)-methanone,
(3,3-difluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(2-ethoxy-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyrrolidin-2-yl]-methanone,
2-{4-[(3S,5S)-5-(3-fluoro-azetidine-1-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-nicotinonitrile,
((S)-3-fluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(4-oxazolo[5,4-b]pyridin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone,
(3-fluoro-azetidin-1-yl)-[(2S,4S)-4-(2-trifluoromethyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyrrolidin-2-yl]-methanone,
2-{4-[(3S,5S)-5-((S)-3-fluoro-pyrrolidine-1-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-nicotinonitrile,
(3-fluoro-azetidin-1-yl)-{(2S,4S)-4-[4-(2-trifluoromethyl-quinolin-4-yl)-piperazin-1-yl]-pyrrolidin-2-yl}-methanone,
((3R*,4S*)-3,4-difluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(2-trifluoromethyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-pyrrolidin-2-yl]-methanone, and
((3R*,4S*)-3,4-difluoro-pyrrolidin-1-yl)-[(2S,4S)-4-(4-oxazolo[5,4-b]pyridin-2yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone; or a pharmaceutically acceptable salt of said compound.

### Claim 7 (depends on 1, 4, 5)

A compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt, for use in therapy.

### Claim 8 (depends on 1, 4, 5)

A pharmaceutical composition comprising:
(a) a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt; and
(b) a pharmaceutically acceptable carrier, vehicle, diluent or excipient.

### Claim 9 (depends on 1, 4, 5)

A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 10 (depends on 1, 4, 5)

A method of treating Type 2 diabetes in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 11 (depends on 1, 4, 5)

A method of treating Type 1 diabetes in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 12 (depends on 1, 4, 5)

A method of treating hyperglycemia in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 13 (depends on 1, 4, 5)

A method of treating metabolic syndrome in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 14 (depends on 1, 4, 5)

A method of treating impaired glucose tolerance in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 15 (depends on 1, 4, 5)

A method of treating diabetic neuropathy in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 16 (depends on 1, 4, 5)

A method of treating diabetic nephropathy in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 17 (depends on 1, 4, 5)

A method of treating diabetic retinopathy in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 18 (depends on 1, 4, 5)

A method of treating diabetic cardiomyopathy in a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1, 4 or 5, or a pharmaceutically acceptable salt of said compound, or a solvate of said compound or salt.

### Claim 19 (depends on 10)

The method of claim 10 wherein said mammal is a human.
